In contrast, a phase II clinical trial found that poly (ADP-ribose) polymerase (PARP) inhibitors also showed promising activity in BRCA1-mutated breast cancer although there were no response in patients with TNBC regardless of BRCA1/2 mutation status [5], and phase III trials are ongoing in BRCA1/2-mutated BC and TNBC [6]. Here, BRCA1 is linked to breast cancer.